Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Regeneron (REGN) Up 20.2% Since Last Earnings Report: Can It Continue?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Thanks so much, everyone. It's funny.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Senior Vice President of Clinical Development Unit Head & Oncology Justin Holko Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the senior biopharma analyst here at Wolfe Research.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript
Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Unit Head & Hematology David Gutstein Conference Call Participants Brian Abrahams - RBC Capital Markets, Research Division Tyler Van Buren - TD Cowen, Research Division David Risinger - Leerink Partners LLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research William Pickering - Sanford C.
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Tyler Van Buren - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Brian Abrahams - RBC Capital Markets, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Alexandria Hammond - Wolfe Research, LLC Christopher Schott - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Presentation Operator Welcome to the Regeneron Pharmaceuticals Third Quarter 2025 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call.
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
